Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) saw a significant decline in short interest in June. As of June 15th, there was short interest totaling 15,401 shares, a decline of 79.5% from the May 31st total of 74,992 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 457,076 shares, the days-to-cover ratio is presently 0.0 days.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on SGIOY. The Goldman Sachs Group raised Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a report on Monday, June 15th. Zacks Research upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a research report on Monday, May 25th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Shionogi & Co., Ltd. Unsponsored ADR presently has a consensus rating of “Buy”.
Get Our Latest Stock Analysis on SGIOY
Shionogi & Co., Ltd. Unsponsored ADR Price Performance
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) last issued its quarterly earnings data on Tuesday, May 12th. The company reported $0.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.15 by $0.03. The company had revenue of $881.71 million for the quarter, compared to the consensus estimate of $895.52 million. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 13.56% and a net margin of 41.08%. As a group, equities research analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.81 earnings per share for the current year.
About Shionogi & Co., Ltd. Unsponsored ADR
Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.
The company’s product portfolio spans both established and innovative therapies.
Read More
- Five stocks we like better than Shionogi & Co., Ltd. Unsponsored ADR
- 3 Waste Stocks Turning AI Investments into Growth
- 3 Overlooked Tech ETFs That Are Quietly Killing It This Year
- 3 ETFs Pairing Market-Beating Returns With High Dividend Yields
- MarketBeat Week in Review – 06/22 – 06/26
Receive News & Ratings for Shionogi & Co. Ltd. Unsponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. Unsponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
